title: Rapamycin graft pretreatment in small bowel and kidney transplantation in the rat.
abstract: The effect of rapamycin (RAPA) as graft pretreatment was evaluated in orthotopic small bowel and kidney allotransplantation (Tx) in the rat. In the small bowel Tx model, six groups were involved, each including three combinations for evaluation of host-versus-graft (HVG) [Lewis (LEW) x Brown Norway (BN) (LBN)-F1-->Lewis], graft-versus-host (GVH) (LEW-->F1), and combined HVG and GVH immune responses (BN-->LEW). RAPA graft pretreatment alone (16 micrograms/ml x 3 ml) was able to induce a modest but significant prolongation of survival in all three combination models compared with controls (P < 0.05). The same was observed for low dose CsA treatment (2 mg/kg/day x 14 days) of the recipient only (P < 0.05). Combination of graft pretreatment with RAPA and CsA recipient treatment produced a marked prolongation of survival especially in HVG response. Recipients treatment with one 48-microgram bolus of RAPA i.v. immediately after graft revascularization failed to achieve any prolongation of survival for the GVH or combined HVG and GVH responses. This seems to exclude a "carry-over" effect of RAPA from graft to recipient. RAPA efficacy was also clearly confirmed in the kidney graft pretreatment model as compared to recipient treatment with an equivalent RAPA dose. These results demonstrate that graft RAPA pretreatment prolongs SB survival after Tx in the rat for HVG, GVH, and bidirectional immune responses. Intragraft interaction with passenger leukocytes or APC function appears as one of the possible mechanisms. RAPA graft pretreatment potentiates low dose CsA recipient treatment suggesting a possible use in clinical organ Tx.
authors.affiliation: Laboratory of Experimental Surgery, Notre-Dame Hospital, University of Montreal, Quebec, Canada.
authors.forename: H
authors.initials: H
authors.lastname: Chen
authors.forename: D
authors.initials: D
authors.lastname: Xu
authors.forename: S
authors.initials: S
authors.lastname: Qi
authors.forename: J
authors.initials: J
authors.lastname: Wu
authors.forename: H
authors.initials: H
authors.lastname: Luo
authors.forename: P
authors.initials: P
authors.lastname: Daloze
mesh_terms: D000818:Animals; D016572:Cyclosporine / Q000494:pharmacology; D006085:Graft Survival / Q000187:drug effects*; D006789:Host vs Graft Reaction / Q000187:drug effects* / Q000276:immunology; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D007421:Intestine, Small / Q000637:transplantation*; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D011090:Polyenes / Q000494:pharmacology*; D011292:Premedication; D051381:Rats; D011914:Rats, Inbred BN; D011917:Rats, Inbred Lew; D020123:Sirolimus; D013997:Time Factors; D014184:Transplantation, Homologous / Q000276:immunology*
chemical_list: D007166:Immunosuppressive Agents; D011090:Polyenes; D016572:Cyclosporine; D020123:Sirolimus